CAR-T Meeting 2025 | The potential use of CAR-T in rheumatologic diseases
In this video, Manel Juan Otero, MD, PhD, Hospital Clinic Barcelona, Barcelona, Spain, comments on the potential use of CAR T-cell therapy for rheumatologic diseases, highlighting the need for management strategies that modify the immune system to increase tolerogenicity. Dr Otero notes that demonstrating the efficacy of novel therapeutic strategies will likely prove difficult, as it requires large cohorts of patients and comparative studies, which may be challenging to conduct. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Rheumatological complications are always a target because it’s a major situation for the patients that don’t have good treatment sometimes and in this case the management of these autoimmune diseases is to, in general, modify to increase tolerogenicity of the situation and modify the immune system. There are too many ways to modify or really, immunosuppressors are one, but when all these different options have success in the treatment of the patient, new options should be tested and one of these new options becomes a different approach, approaches in CAR T-cells...
Rheumatological complications are always a target because it’s a major situation for the patients that don’t have good treatment sometimes and in this case the management of these autoimmune diseases is to, in general, modify to increase tolerogenicity of the situation and modify the immune system. There are too many ways to modify or really, immunosuppressors are one, but when all these different options have success in the treatment of the patient, new options should be tested and one of these new options becomes a different approach, approaches in CAR T-cells. One of them is to kill the cells, as has been also used with antibodies, and this killing of the cells is more deep when you use CAR-T than when you use antibodies, this is clear, and this allows to have a new opportunity to obtain remission of this difficult situation.
But the problem of these approaches, of these diseases, is that it’s not so easy to demonstrate efficacy because even if you can demonstrate to create better propulsion of better scores in a lot of parameters, finally everybody is trying to find if this treatment is good enough to substitute other treatments. And this will need a big number of patients, comparisons, and most of the comparisons become for companies that have the drugs, and it’s not easy to arrive to have these comparative studies that demonstrate the approach and the efficacy of the proposed CAR.
So I think it’s a clear new option, but it will take some time to arrive to have a clear approval of this because maybe we obtain some approval from situations that are not other options when the things are not good enough, but it will be difficult to substitute conventional immunosuppressors or immunosuppressive approaches to solve the situation of the patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
